Abstract
Introduction
Cancer today has become the leading cause of death worldwide, which accounted for approximately 8.2 million deaths in the year 2012 [1] . According to WHO survey report, the most common cause of cancer deaths were observed for lung cancer (1.59 million deaths), liver cancer (745 000 deaths), stomach cancer (723 000 deaths), colorectal cancer (694 000 deaths), breast cancer (521 000 deaths), esophageal cancer (400 000 deaths) [1] . Epidemiologically, it was observed that approximately more than 60% of the world's total new annual cases along with 70% of the world's cancer deaths occured in Africa, Asia and Central and South America [1] . This disease burden had led to the invention of various effective conventional treatments [1] . However, there were very few of the treatments found to be effective in improving the quality of life of cancer patients undergoing different regimen of treatments [1] . Therefore, the present paper highlighted the use of Phytocannabis as an alternative treatment to alleviate the side effects produced in the treatment of cancer [1] . Phytocannabinoids weredefined as the cannabinoid compounds that were obtained from the femaleCannabis sativa or Cannabis indicaplant which wasfound to act on cannabinoid receptors in cells that modulated neurotransmitter release in the brain [1, 2] . The principal cannabinoids in the cannabis plant included delta-9-tetrahydrocannabinol (THC), cannabidiol (CBD), and cannabinol (CBN) [1, 2] . The known chemical composition of Cannabis sativa kept constantly changing [2] . From 2005 to 2015, the number of cannabinoids identified in the whole plant increased from 70 to 104 and other known compounds in the plant increased from some 400 to around 650 [2] . Nevertheless, there were some relatively good data on the prevalence of Phytocannabis in some parts of the world [2] . Levels of lifetime use differ considerably between countries, ranging from around one third of adults in Denmark, France and the United Kingdom, to 8% or less than 1 in 10 in Bulgaria, Romania and Turkey [2] .
Aim
The main objective of this review was:
a. To understand the role of Phytocannabis and its derivatives in the treatment of cancer associated symptoms, like pain, nausea and vomiting, b. To assess clinical safety and efficacy of Phytocannabis in reducing accompanied symptoms due to result of cancer, Chemotherapy or Radiotherapy treatment, c. To evaluate the potential therapeutic value of Phytocannabis in preventing cancerous tumor growth, as well as, alleviating and reduction in pain, nausea and vomiting. d. To collect more data on the increasing use of PHYTOCANNABIS in CANCER.
Search methodology
The primary and foremost point that was focused throughout the article review was 'Cannabis and Cancer'. All types of studies were included in this regard. Moreover, children, Adolescents and Adults suffering from Cancer were included in this review. The methodology being adopted for the relevant literature review, searching the databases like, PUBMED, Cochrane Library, MEDLINE, EMBASE, Clinical trials.gov by using keywords such as, 'cannabis', 'marijuana', 'cannabinoids', 'tetrahydrocannabinol', 'THC', 'cannabidiol', 'CBD', 'cannabidivarin', 'CBDV', 'cancer', 'nausea' and 'vomiting' was utilized. Moreover, a greater number of google searches were done to gather reliable and valid information from websites primarily focusing on safety and efficacy of medicinal cannabis used in cancer patients. The search was confined to studies being published in English language. Moreover, PRISMA methodology was adopted for inclusion of relevant studies. 
Data interpretation
On the basis of the data collected and retrieved, following observations were made in the form of plots and graphs. 
Discussion
From the literature and data reviewed, it was observed that 37 studies were identified with Phytocannabis use in cancer treatment, amongst which only 2 trials reported for its efficacy in children as compared to that on adults in 35 trials . Nabilone (Phytocannabis) when administered orally was well tolerated with marked improvement in pain intensity, improved appetite, reduced nausea and vomiting along with minimal side effects such as, dizziness, drowsiness, hallucinations, dry mouth, vertigo, postural hypotension, sleep disturbances and fatigue . In some studies, where no significant improvement was observed, still the patient's choice of preference was Oral Nabilone in either capsule form or as herbal tea . When Phytocannabis (Cannabis) was administered sublingually in the form of Sprays, there was marked great reduction in pain intensity accompanied by reduced nausea and vomiting along with minimal side effects of loss in appetite . When Phytocannabis (Delta-9-THC) was administered orally was found to be useful in palliation of chemosensory alterations and improved food taste and appetite, reduced nausea and vomiting along with less concentration ability, less social interaction, sedation, mental clouding and blurred vision . In a study conducted by Johnson, J.R. et al. (2010) , THC: CBD was found to be more effective in reduction of pain in cancer patients [8] . On the other hand, mild psychological effects were found to be associated with inhaled form of Phytocannabis [8] .
On the other hand, it was observed that 2 uncontrolled case reports presented with intervention of Phytocannabis (Delta-9-THC) led to reduction in nausea and vomiting that was induced by chemotherapy and radiotherapy treatments [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . It was also found that due to this intervention there was marked improvement in appetite and pain [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . From the open-labeled studies conducted, it was observed that 15 studies were identified from the year 1984to 2015 for the use of Phytocannabis in the treatment of cancer and treatment related side effects [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Moreover, it was observed that Nabilone when administered orally was well tolerated with significant improvement in pain intensity, reduced nausea and vomiting, improved insomnia and night sweats, reduced distress and reduced radiotherapy-induced sickness [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . The intervention of the Phytocannabis Nabilone orally produced mild side effects of anxiety and depression [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Secondly, when Phytocannabis was administered orally, inhaled/smoked or sublingually, it was highly effective in reduction of pain intensity along with improved appetite, reduced nausea and vomiting, with minimal side effects such as sedation, dizziness and Xerostomia [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . Another form of Phytocannabis, namely, Delta-9-THC when administered orally was also well tolerated by increased appetite and reduced nausea and vomiting with minor side effects of weight loss and dizziness [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] . According to Guzman, M. et al. (2006) study, Phytocannabis in the form of Delta-9-THC when administered intracranially to the brain tumor patients after undergoing Whole Brain Radiotherapy showed anti-proliferative action on tumor cells thereby reduced the associated symptoms of Radiotherapy [18] . However, much insight into its effectiveness is required for its standardization [18] .
Moreover, it was seen that only two out of 15 clinical trials were conducted on children suffering from cancer [55, 56] . This in part reflected difficulties in collecting comparable data onillicit drug usage [55, 56, 57] . Some countries did not conduct surveys of drug use, some conducted surveys annually and others conducted them less frequently [55, 56, 57] . Of those surveys that were conducted, there was variation between countries in assessing frequency of use, and age groups were divided differently or differed in the settings in which the adolescents and young adults were surveyed [55, 56, 57] .
On the whole, it could be concluded from this presented report that there had been more number of Randomized controlled trials in comparison to open-labelled and uncontrolled case studies as retrieved from 1975-2015. During those subsequent 40 years, there were comparatively less number of clinical trials for the use of Phytocannabis and its derivatives for the cancer-related and cancer treatment related studies as compared to the increased burden of the disease globally. Moreover, only few studies focused on the subjects that consisted children which was a major pitfall in finding the compassionate treatment for children group as well who were at the same risk level of developing the disease. Phytocannabis (Nabilone) oral route of administration either alone or as add-on therapy was found to be more preferred, safe and effective to be used in patients who underwent either chemotherapy or radiotherapy treatment.
Conclusion
The presented report contributed to the development of evidence based use of Phytocannabis for cancer treatment which ultimately contributed to the improvement of the quality of life of people suffering from cancer who underwent either chemotherapy or radiotherapy treatments. Therefore, it was concluded that the treatment decisions should be based on standard principles of medical-care ethics -that provided equitable access to treatment and psychosocial support that best meet the needs of the individual cancer patient [58] . Treatment should respect and validate the autonomy of the individual, with patients being fully informed about the risks and benefits of treatment choices [58] . The development and maintenance of Phytocannabis treatment services evidently needs to take place within the broader system of health-care financing and provision in a given country [58] . The presented report thus, highlighted the benefic use of Phytocannabis and its derivatives in the treatment of cancer patients thereby by enhanced quality of life of those patients with minimal side effects being associated with the prolonged disease. In a nutshell, Phytocannabis (Nabilone, Delta-9-THC, Cannabis) in the form of capsules or inhaled form was found to be safe and effective to be used in Metastatic cancer, Advanced cancer, Neuropathic pain, nausea and vomiting induced by Chemotherapy and radiotherapy, Head and Neck cancer, Malignant Melanoma, Hematologic cancer, Brain tumor, Gastrointestinal carcinoma, Osteogenic sarcoma, Liver cancer, Bone cancer, Lungs cancer, Non-seminatous Testicular cancer, Abdominal cancer and Soft tissue sarcoma.
Future directions
There were certain areas that required more research as mentioned below:
1. There were none to minimal standard measures of the Phytocannabis and its content used in most of the countries and regions worldwide. 2. Global data were required on the frequency of Phytocannabis use (more than once daily, daily, near daily, weekly, etc.) and the prevalence of health and social consequences. 3. Data was required on the typical doses of Phytocannabis (smoked, vaporized, ingested) with the potency of Phytocannabis for long term usage and its impact on health and quality of life of the cancer patients. Larger cohort and better designed case-control studies were needed to better understand the control for benefic effects. 4. Global assessments were needed to establish the relationship between the use of Phytocannabis and other conventional drugs. 5. Most of the studies on risk and protective factors for Phytocannabis use had been conducted in a limited number of high-income countries. There was some uncertainty as to whether the same risk factors prevailed in low-and middle-income countries.
More research was required on Phytocannabis use in low-and middle-income countries for the treatment of cancer and related symptoms.
